This quality ASX share has trailed the broader market over the past year as investors fret over growth, cost pressures, and execution risks.
Sonic Healthcare Ltd (ASX: SHL) shares have lost some serious ground in the past year, 23% to $21.97 at the time of writing.
This ASX share is worth considering if you are looking for income, quality and resilience. Let's take a closer look.
Image source: Getty Images
Resilient compounder
Sonic Healthcare isn't a high-flying growth story — the ASX share is a steady compounder. Demand is defensive by nature and largely independent of economic cycles.
The ASX diagnostics giant runs pathology and imaging businesses across Australia, Europe, the US, and the UK. That global footprint gives it diversification that few ASX healthcare names can match.
What really sets Sonic Healthcare apart is resilience. Medical testing demand doesn't vanish in a downturn or during structural tailwinds. Ageing populations and a growing focus on preventative care keep volumes ticking higher.
Management of the ASX share has also expanded through disciplined acquisitions, building scale while defending margins.
That said, this isn't a rocket ship. Cost inflation, labour shortages, and the occasional integration hiccup can slow earnings growth. And when momentum cools, the market's patience can wear thin.
Gradually lifting payouts
Where Sonic Healthcare shines is income reliability. It pays dividends twice a year and has a long record of maintaining or gradually lifting payouts. Bell Potter expects partially franked payouts of 109 cents per share in FY 2026 and 111 cents per share in FY 2027.
Based on its current share price of $21.97, this equates to dividend yields of 4.8% and 4.9%, respectively. That's attractive for a defensive ASX healthcare share, and it's backed by recurring cash flow, not one-off gains.
What do brokers think?
For investors, this ASX share offers a blend of steady growth and dependable income. Bell Potter believes Sonic Healthcare offers an appealing combination of income and share price upside. The broker expects Sonic to return to double-digit earnings growth in FY 2026, driven largely by acquisitions.
Bell Potter recently initiated coverage with a buy rating and a $33.30 12-month price target. That points to 34% upside from the current levels.
Bell Potter is way more bullish than the consensus target of $25.65, which suggests about 17% upside. Add in a forecast 4.9% dividend yield, and total potential returns could comfortably exceed 20%.
